We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
1 own
4 watching
Current Price
$7.1
$-0.32
(-4.31%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
387.88M
52-Week High
16.6
52-Week Low
3.33
Average Volume
0.3M
Dividend Yield
--
P/E Ratio
--
Market Capitalization387.88M
52-Week High16.6
52-Week Low3.33
Average Volume0.3M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company s product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Globe Newswire
12days ago
SOUTH SAN FRANCISCO, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will ...
Ticker Report
23days ago
Sutro Biopharma (NASDAQ:STRO Get Rating) and AlloVir (NASDAQ:ALVR Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability...
Globe Newswire
1month ago
--Results from compassionate use program highlight promising activity of STRO-002 in children with rare form of acute myeloid leukemia, that is highly refractory to all standard-of-care therapies--SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the ...
Market News Video
1month ago
In trading on Tuesday, shares of Sutro Biopharma Inc (STRO) crossed above their 200 day moving average of 6.75, changing hands as high as 6.95 per share. Sutro Biopharma Inc shares are currently trading up about 6.5% on the day...
PR Newswire
4 months ago
Thinking about buying stock in La Jolla Pharmaceutical, Toughbuilt Industries, Waitr Holdings, Sutro Biopharma, or Magnachip Semiconductor? Thinking about buying stock in La Jolla Pharmaceutical, Toughbuilt Industries, Waitr Holdings, Sutro Biopharma, or Magnachip Semiconductor? PR Newswire NEW...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$7.1
$-0.32
(-4.31%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00